Eisele Jeffrey — SEC Form 4 filings
SEC reporting owner CIK 1827326. 9 Form 4 filings on record with FilingPulse; latest filed 2025-01-30.
Transaction summary — filings shown
Covers all 9 filings on record, filed 2024-01-17 to 2025-01-30. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 10 legs across 9 filings — 17,776 shares, $1,083,764 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 2.
- Largest priced transaction: sale of 7,378 shares @ $63.69 ($469,905) in Apellis Pharmaceuticals, Inc., filed 2024-01-24.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Apellis Pharmaceuticals, Inc. (APLS) | Chief Development Officer | 9 | — | 10 legs · 17,776 sh · $1,083,764 | 2 |
Form 4 filings — Eisele Jeffrey
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2025-01-30 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 278 @ $29.52 | EDGAR |
| 2025-01-23 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 1,291 @ $30.43 | EDGAR |
| 2025-01-14 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 264 @ $28.70 | EDGAR |
| 2024-12-27 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 63 @ $33.09 | EDGAR |
| 2024-01-31 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 279 @ $64.14 · Sale (S): 971 @ $65.53 | EDGAR |
| 2024-01-24 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 7,378 @ $63.69 | EDGAR |
| 2024-01-23 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 1,607 @ $65.00 | EDGAR |
| 2024-01-18 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 5,207 @ $65.58 | EDGAR |
| 2024-01-17 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Grant/award (A): 19,508 @ $0 · Sale (S): 438 @ $66.81 · Grant/award (A): 28,367 (derivative) @ $66.30 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1827326 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →